This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nosrati, M. Articles by Kashani-Sabet, M. Search for Related Content PubMed PubMed Citation Articles by Nosrati, M. Articles by Kashani-Sabet, M.

Antitumor Activity of Systemically Delivered Ribozymes Targeting Murine Telomerase RNA

¹ Auerback Melanoma Research Laboratory, Cutaneous Oncology Program, Department of Dermatology and ² Genome Analysis Core Facility, University of California San Francisco Cancer Center, and ³ Department of Biochemistry and Biophysics, University of California San Francisco, and ⁴ California Pacific Medical Research Institute, San Francisco, California

ABSTRACT

Purpose: To test ribozymes targeting mouse telomerase RNA (mTER) for suppression of the progression of B16-F10 murine melanoma metastases in vivo.

Experimental Design: Hammerhead ribozymes were designed to target mTER. The ribozyme sequences were cloned into a plasmid expression vector containing EBV genomic elements that substantially prolong expression of genes delivered in vivo. The activity of various antitelomerase ribozymes or control constructs was examined after i.v. injection of cationic liposome:DNA complexes containing control or ribozyme constructs. Expression of ribozymes and mTER at various time points were evaluated by quantitative real-time PCR. Telomerase activity was examined using the telomeric repeat amplification protocol.

Results: Systemic administration of cationic liposome:DNA complexes containing a plasmid-expressed ribozyme specifically targeting a cleavage site at mTER nucleotide 180 significantly reduced the metastatic progression of B16-F10 murine melanoma. The antitumor activity of the anti-TER 180 ribozyme in mice was abolished by a single inactivating base mutation in the ribozyme catalytic core. The EBV-based expression plasmid produced sustained levels of ribozyme expression for the full duration of the antitumor studies. In addition to antitumor activity, cationic liposome:DNA complex-based ribozyme treatment also produced reductions in both TER levels and telomerase enzymatic activity in tumor-bearing mice.

Conclusions: Systemic, plasmid-based ribozymes specifically targeting TER can reduce both telomerase activity and metastatic progression in tumor-bearing hosts. The work reported here demonstrates the potential utility of plasmid-based anti-TER ribozymes in the therapy of melanoma metastasis.

This article has been cited by other articles:

				S. Z. Torabian, D. de Semir, M. Nosrati, S. Bagheri, A. A. Dar, S. Fong, Y. Liu, S. Federman, J. Simko, C. Haqq, et al. Ribozyme-Mediated Targeting of I{kappa}B{gamma} Inhibits Melanoma Invasion and Metastasis Am. J. Pathol., March 1, 2009; 174(3): 1009 - 1016. [Abstract] [Full Text] [PDF]

				E. J. Chapman, G. Kelly, and M. A. Knowles Genes Involved in Differentiation, Stem Cell Renewal, and Tumorigenesis Are Modulated in Telomerase-Immortalized Human Urothelial Cells Mol. Cancer Res., July 1, 2008; 6(7): 1154 - 1168. [Abstract] [Full Text] [PDF]

				F. Yang, R. R. Xian, Y. Li, T. S. Polony, and K. L. Beemon Telomerase reverse transcriptase expression elevated by avian leukosis virus integration in B cell lymphomas PNAS, November 27, 2007; 104(48): 18952 - 18957. [Abstract] [Full Text] [PDF]

				L. Kelland Targeting the Limitless Replicative Potential of Cancer: The Telomerase/Telomere Pathway Clin. Cancer Res., September 1, 2007; 13(17): 4960 - 4963. [Abstract] [Full Text] [PDF]

				S. Bagheri, M. Nosrati, S. Li, S. Fong, S. Torabian, J. Rangel, D. H. Moore, S. Federman, R. R. LaPosa, F. L. Baehner, et al. Genes and pathways downstream of telomerase in melanoma metastasis PNAS, July 25, 2006; 103(30): 11306 - 11311. [Abstract] [Full Text] [PDF]

				A. Goldkorn and E. H. Blackburn Assembly of Mutant-Template Telomerase RNA into Catalytically Active Telomerase Ribonucleoprotein That Can Act on Telomeres Is Required for Apoptosis and Cell Cycle Arrest in Human Cancer Cells Cancer Res., June 1, 2006; 66(11): 5763 - 5771. [Abstract] [Full Text] [PDF]

				S. LI and E.H. BLACKBURN Expression and Suppression of Human Telomerase RNA Cold Spring Harb Symp Quant Biol, January 1, 2006; 71(0): 211 - 215. [Abstract] [PDF]

				G.J. HANNON, F.V. RIVAS, E.P. MURCHISON, and J.A. STEITZ The Expanding Universe of Noncoding RNAs Cold Spring Harb Symp Quant Biol, January 1, 2006; 71(0): 551 - 564. [Abstract] [PDF]

				E. H. Blackburn Telomerase and Cancer: Kirk A. Landon - AACR Prize for Basic Cancer Research Lecture Mol. Cancer Res., September 1, 2005; 3(9): 477 - 482. [Full Text] [PDF]

				S. Li, J. Crothers, C. M. Haqq, and E. H. Blackburn Cellular and Gene Expression Responses Involved in the Rapid Growth Inhibition of Human Cancer Cells by RNA Interference-mediated Depletion of Telomerase RNA J. Biol. Chem., June 24, 2005; 280(25): 23709 - 23717. [Abstract] [Full Text] [PDF]